dc.contributor.author | Ekizoglu, Esme | |
dc.date.accessioned | 2021-03-03T11:36:17Z | |
dc.date.available | 2021-03-03T11:36:17Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Ekizoglu E., "Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)", TURKISH JOURNAL OF NEUROLOGY, cilt.24, sa.2, ss.199-200, 2018 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_28d0cd86-85e2-4d74-8f12-28131fc93fac | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/32290 | |
dc.identifier.uri | https://doi.org/10.4274/tnd.37233 | |
dc.language.iso | eng | |
dc.subject | Nöroloji | |
dc.subject | Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | KLİNİK NEUROLOJİ | |
dc.title | Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study) | |
dc.type | Makale | |
dc.relation.journal | TURKISH JOURNAL OF NEUROLOGY | |
dc.contributor.department | İstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
dc.identifier.volume | 24 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 199 | |
dc.identifier.endpage | 200 | |
dc.contributor.firstauthorID | 248772 | |